Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop of 5.15% in its stock price, settling at $2.76 per share. The trading volume reached 782,917 shares with a turnover rate of 0.37% and price fluctuations at 8.25%.
Recent financial reports indicate that the company recorded zero revenue, a net loss of $66.36 million, and earnings per share (EPS) of -$0.35. The gross profit stood at a negative $3.64 million, and the price-to-earnings (P/E) ratio was -1.74.
Out of 18 rating institutions, 72% recommended a buy, while 28% advised holding. No institutions recommended selling the stock.
The biotechnology sector, where Allogene Therapeutics operates, experienced a 0.42% overall decline. Notable gains in the sector included Coeptis Therapeutics Holdings Inc, Nkgen Biotech Inc, and Capricor Therapeutics, Inc. Meanwhile, Aditxt, Inc., Seelos Therapeutics, Inc., and Gri Bio, Inc. demonstrated significant trading activity with high turnover rates of 215.85%, 60.74%, and 58.28%, respectively. Stocks with large price swings included Coeptis Therapeutics Holdings Inc, Tc Biopharm (Holdings) Plc, and Surrozen Inc, with amplitude changes of 87.30%, 85.25%, and 48.53% respectively.
Allogene Therapeutics is a clinical-stage biotech company focused on developing gene-engineered allogeneic T-cell products for cancer and autoimmune diseases. Their innovative CAR T-cell therapies are sourced from healthy donors, enabling wider patient eligibility and scalability. The company's revenue primarily comes from collaboration and licensing agreements supporting their R&D efforts.
